Efficacy of piracetam in children with encephalitis

Evaluation of efficacy of add on oral piracetam in children with acute encephalitis syndrome aged 1 month-18 years: a single-blind randomized controlled trial - PAES

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051722

Enrollment

200

Registered

2023-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G049- Encephalitis, myelitis and encephalomyelitis, unspecified

Interventions

Intervention1: Standard care (intravenous acyclovir) and add on oral piracetam: Standard care (intravenous acyclovir) 20 mg/kg/dose q8hourly for 7 days and add on oral piracetam 50 mg/kg/day once dail

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinical diagnosis of acute encephalitis syndrome

Exclusion criteria

Exclusion criteria: Preexisting developmental delay Parents not giving informed consent

Design outcomes

Primary

Measure	Time frame
Functional status scale scoreTimepoint: At 0-week (baseline) and at 12-weeks	—

Secondary

Measure	Time frame
Pediatric cerebral performance category scoreTimepoint: At 0-week (baseline) and at 12-weeks	—

Countries

India

Contacts

Public ContactGarima Singh

AIIMS, RISHIKESH

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026